UC

Standard Uranium Intersects Anomalous Radioactivity, Prospective Structure and Alteration in Multiple Drill Holes at Atlantic Project; Concludes Inaugural Drill Program

Retrieved on: 
Thursday, April 11, 2024
ICP-MS, Standards Council of Canada, Digestion, Uranium, Gamma, Boron, Denison Mines, News, Rock, Tourmaline, Hematite, Hole, CPS, QA/QC, Gold, SRC, Anomaly, Radioactive decay, UC, Uranium mining

Core photos of prospective alteration, structure, and radioactivity intersected during the inaugural drill program are presented in Figure 3, 4, and 5.

Key Points: 
  • Core photos of prospective alteration, structure, and radioactivity intersected during the inaugural drill program are presented in Figure 3, 4, and 5.
  • Core photos from drill hole ATL-24-002 highlighting significant structure and alteration intersected in the Athabasca sandstone and basement rocks.
  • Core photos from drill hole ATL-24-004a highlighting basement structure and alteration zones intersected associated with anomalous radioactivity.
  • Core photos from drill hole ATL-24-005a highlighting structure and alteration intersected in the Athabasca sandstone and basement rocks.

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

Retrieved on: 
Wednesday, April 10, 2024
Trial of the century, Publication, PDE4, IBD, Therapy, Patient, Autoimmunity, UC, Pharmaceutical industry

Carlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it presented at IBD Innovate: Product Development for Crohn’s & Colitis™ held April 9-10, 2024 in Cambridge, MA. As part of the conference, Christophe Mellon, Chief Executive Officer of Giiant Pharma, Inc., the Company’s research partner, and Dr. Mitch Jones, Chief Medical Officer of Palisade Bio gave an oral presentation titled, “Advancing PALI-2108: Discovery to Strategy Positioning,” which discussed the development of PALI-2108, its differentiation and positioning in the competitive landscape as well as a clinical pathway towards late-stage development. The presentation is accessible on the Publications page under the Science section of Palisade Bio’s website, www.palisadebio.com. “We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108. We continue to generate a growing body of data from PALI-2108 for the treatment of UC and remain on track to launch our Phase 1 clinical study later this year," commented Dr. Jones.

Key Points: 
  • The presentation is accessible on the Publications page under the Science section of Palisade Bio’s website, www.palisadebio.com .
  • “We were pleased to participate with Giiant at the premier IBD conference and provide further information on PALI-2108.
  • As previously announced, the development of PALI-2108 is supported by a $500,000 research program funding agreement with Giiant from the US Crohn’s and Colitis Foundation, through its IBD Ventures program.
  • PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.

Synedgen Completes IND-Enabling Studies for Two Parallel Programs for Lead Asset MIIST305

Retrieved on: 
Thursday, April 25, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Mortality, FDA, Ulcerative colitis, Radiation, Drug discovery, Safety, MD, Trial of the century, Doctor of Philosophy, IND, Disease, Patient, Chemistry, CMC, GLP, Physician, Good laboratory practice, Toxicology, UC, Pharmaceutical industry

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced it has completed IND-enabling studies for its lead candidate, MIIST305.

Key Points: 
  • Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced it has completed IND-enabling studies for its lead candidate, MIIST305.
  • MIIST305 is being developed for two parallel programs, an indication for ulcerative colitis (UC) and a medical countermeasure for gastrointestinal acute radiation syndrome (GI-ARS).
  • Within a year, Synedgen plans to open an Investigational New Drug (IND) application for MIIST305 and initiate a Phase 1 clinical study to support both programs.
  • Synedgen was awarded a $4.4 million grant from the Congressionally Directed Medical Research Program (CDMRP) to fund some of MIIST305’s preclinical, IND-enabling studies.

YC-Backed Yoneda Labs Raises $4 Million Seed Led by Khosla Ventures to Build Foundation Model for Chemists

Retrieved on: 
Friday, April 26, 2024
Science, Software, Biotechnology, Research, Pharmaceutical, Health, Artificial Intelligence, Technology, University, Machine learning, Khosla Ventures, YC, Literature, Automation, Chemistry, Robotics, University of California, Berkeley, Y Combinator, Drug development, Drug discovery, Running, Algorithm, UC, Pharmaceutical industry

Yoneda Labs , the Y Combinator startup building a foundation model for chemists working in drug discovery, today announced it has raised $4 million in seed capital from Khosla Ventures, 500 Emerging Europe, 468 Capital, Fellows Fund, and Y Combinator.

Key Points: 
  • Yoneda Labs , the Y Combinator startup building a foundation model for chemists working in drug discovery, today announced it has raised $4 million in seed capital from Khosla Ventures, 500 Emerging Europe, 468 Capital, Fellows Fund, and Y Combinator.
  • “At Yoneda, our vision is to build a foundation AI model that analyzes and predicts what will happen before a chemist has to run their experiment.
  • Yoneda Labs was founded by a group from the University of Cambridge with backgrounds in chemistry, robotics, and machine learning.
  • During their time at YC, the team identified 20,000 chemical reactions to generate proprietary data for their foundation model.

Equinox Hotels Revolutionizes Sleep Tourism with Inaugural Global Sleep Symposium

Retrieved on: 
Wednesday, April 24, 2024
Other Health, Other Travel, Other Consumer, Lodging, Destinations, General Health, Travel, Women, Men, Science, Vacation, Consumer, Other Science, Health, Research, Relaxation, Foodservice, Lead, Brain, University, Psychology, TED (conference), Yoga, Sleep, Hotel, Fasting, Movement, University of California, Berkeley, Melksham, Multimedia, Central nervous system, Equinox, Regeneration, Electronic, Longevity, Sound, UC

Equinox Hotels, renowned for its pioneering approach to high-performance luxury hospitality and sleep-focused innovation, announces the launch of its inaugural Global Sleep Symposium at Equinox Hotel New York on June 19th and 20th.

Key Points: 
  • Equinox Hotels, renowned for its pioneering approach to high-performance luxury hospitality and sleep-focused innovation, announces the launch of its inaugural Global Sleep Symposium at Equinox Hotel New York on June 19th and 20th.
  • This visionary two-day overnight event is set to redefine the landscape of sleep tourism by uniting global experts in sleep health and performance with Equinox Hotel's dynamic programming centered on movement, nutrition, regeneration, and community.
  • The two-day symposium signifies the culmination of years of boundary-pushing sleep innovation, positioning Equinox Hotels as the preeminent nexus for leaders in the sleep industry and enthusiasts alike, to converge, collaborate, and propel the discourse on sleep science and sleep tourism to new heights.
  • The Equinox Hotels Global Sleep Symposium transcends mere discussion; it offers an immersive experience aimed at enhancing every aspect of sleep quality, providing attendees with firsthand interactions to elevate their sleep understanding and practice.

Celestial AI Announces Appointment of Diane Bryant to Board of Directors

Retrieved on: 
Wednesday, April 24, 2024
Software, Networks, Hardware, Electronic Design Automation, Data Management, Technology, Semiconductor, Other Technology, Cloud, Sale, University, Broadcom Inc., Woman, Haemonetics, UTC, Photonics, AI, Innovation system, Google Cloud, University of California, Davis, Adviser, Artificial intelligence, Engineering, Intel, Diane Bryant, Business Insider, United Technologies, Female, Celestial, UC, Management

Celestial AI™ , creator of the Photonic Fabric™ optical interconnect technology platform, today announced the appointment of Diane Bryant to the Company’s Board of Directors (“the Board”) effective April 11, 2024.

Key Points: 
  • Celestial AI™ , creator of the Photonic Fabric™ optical interconnect technology platform, today announced the appointment of Diane Bryant to the Company’s Board of Directors (“the Board”) effective April 11, 2024.
  • In addition to her board appointments, she also serves as the chair of the UC Davis Chancellor’s Board of Advisors.
  • “We are thrilled to welcome Diane to our board of directors,” said David Lazovsky, Celestial AI founder and CEO.
  • “Diane’s extensive experience as a technology industry leader, CEO and board member make her an ideal addition to the Celestial AI team.

Mitel Unveils Combined Portfolio Strategy, Emphasizing Hybrid, Vertically Integrated, and Multimodal Solutions

Retrieved on: 
Tuesday, April 23, 2024
VoIP, Software, Networks, Professional Services, Hardware, Business, Apps, Applications, Technology, Security, Marketing, Communications, Other Technology, Telecommunications, Unify, Cloud, DECT, Public sector, Mitel, Investment, Hospital, Transport, Consultant, Frost, Senior, Product management, Acquisition, Multimedia, Government, VCCS, Organization, UC, Risk management

View the full release here: https://www.businesswire.com/news/home/20240423338581/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240423338581/en/
    Mitel's new combined portfolio strategy introduces a comprehensive suite of proven solutions and services following last year’s acquisition of Unify.
  • Mitel’s portfolio strategy focuses on three key areas:
    Hybrid Cloud UC Solutions: Mitel has long championed the need to provide flexibility of deployment model, offering customers a proven mix of private cloud, public cloud, and on-premise solutions.
  • The newly combined portfolio offers a wealth of solutions uniquely suited to meet the complex requirements of industries such as healthcare, financial services, public sector, and hospitality.
  • Already the global leader in cordless DECT devices, Mitel’s go-forward portfolio will deliver more next-generation UC solutions to address the specific needs of on-the-go professionals and remote workers.

BenevolentAI Provides an Update on Its Business Priorities

Retrieved on: 
Tuesday, April 23, 2024
Health, Pharmaceutical, Technology, Artificial Intelligence, Software, Knowledge, Phases of clinical research, Ulcerative colitis, Euronext Amsterdam, Software as a service, Science, Patient, BAI, Drug discovery, Merck, UC, Pharmaceutical industry

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities.
  • Going forward the Company will focus on its AI-driven drug discovery collaboration and proprietary pipeline revenue generating pillars, following recent successes in these areas.
  • The Board believes this focus will likely bring the greatest potential return for shareholders.
  • BenevolentAI is an AI augmented drug discovery company uniting science and technology with the aim to develop life-changing medicines for patients.

Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis

Retrieved on: 
Wednesday, April 17, 2024
Research, Genetics, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Patient, Lupus nephritis, Nephritis, Safety, Lupus Research Alliance, Tissue, CD20, CD38, Lupus, Rituximab, Autoimmune disease, CD19, Cyclophosphamide, LN, NHL, Immune system, Clinical trial, Therapy, NK, Network, UC

AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.

Key Points: 
  • AlloNK is a non-genetically modified, allogeneic, cryopreserved NK cell therapy candidate being developed to enhance the activity of B-cell targeting monoclonal antibodies to drive B-cell depletion.
  • To our knowledge, this is the first time a patient has received an allogeneic NK cell therapy candidate in a U.S. clinical trial for treatment of an autoimmune disease.
  • Artiva is collaborating with Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, to support the evaluation of AlloNK for LN.
  • The Network, overseen by Lupus Therapeutics, is comprised of leading research centers throughout North America with the purpose of accelerating and optimizing lupus clinical trials.

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Inflammation, Safety, Outline, CNS, IBD, Therapy, Patient, Histology, DSM-IV codes, NEJM, MRM, Inflammatory Bowel Diseases, UC, KU Leuven, CGMP, Pharmaceutical industry

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis.

Key Points: 
  • MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis.
  • MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy.
  • The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks.
  • Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002.